Original Source(s)
Related Content
Why FDA Said No to a Melanoma Drug
Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.
by Arthur Allen
May 15, 2026
-
9 min
FDA expands gastroesophageal cancer options
Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.
August 25, 2026
-
2 min
FDA Expands Gene Therapy for Younger Patients
Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
July 2, 2026
-
3 min
